Twenty Anti-Citrullinated Peptide Antibody (ACPA) positive, shared epitope positive Rheumatoid Arthritis patients with nil-to-moderate disease activity will be randomised in an allocation ratio of 1:1:1:1:1. Here, PRTN3 is linked to rheumatoid arthritis.